Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic diversity of urinary bladder cancer and the risk of recurrence based on mutation analysis.

Neoplasma - 1 Jan 2016

Traczyk-Borszynska M, Borkowska E, Jablonowski Z, Jedrzejczyk A, Pietrusinski M, Kaluzewski B, Sosnowski M, Borowiec M

Abstract excerpt

The aim of the study was to assess the genetic diversity of bladder cancer and determine the suitability of a proposed molecular marker panel to monitor the course of bladder cancer patients. The study involved 185 patients with diagnosed bladder cancer. The genetic diversity of the bladder cancer was evaluated by the prevalence of mutations in the TP53, HRAS, FGFR3 and WWOX genes. Mutations were detected in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neoplasm Recurrence, Local
Share to Proto-Oncogene Proteins p21(ras)

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Receptor, Fibroblast Growth Factor, Type 3

Share to Tumor Suppressor Protein p53

Share to Tumor Suppressor Proteins

Share to Urinary Bladder Neoplasms

Share to WW Domain-Containing Oxidoreductase

Source

Identifiers

PMID: 27596295
DOI: 10.4149/neo_2016_614

Genes

FGFR3
WWOX
HRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic diversity of urinary bladder cancer and the risk of recurrence based on mutation analysis.PMID 27596295Read ↗

[Recent advances in bladder urothelial carcinogenesis].Semantic proximity Read ↗

Bladder cancer: molecular determinants of personalized therapy.Semantic proximity Read ↗

FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients.Semantic proximity Read ↗

TP53 Mutation for Prediction of Tumor Recurrence and Metastasis in Bladder Cancer PatientsSemantic proximity Read ↗

Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations.Semantic proximity Read ↗

Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.Semantic proximity Read ↗

In-depth investigation of the molecular pathogenesis of bladder cancer in a unique 26-year old patient with extensive multifocal disease: a case report.Semantic proximity Read ↗

FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.Semantic proximity Read ↗

The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancerSemantic proximity Read ↗

FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.Semantic proximity Read ↗

Lower mutant-allele tumor heterogeneity is a biomarker in FGFR3-mutant bladder cancer for better prognosis.Semantic proximity Read ↗

Molecular Determinants of Tumor Recurrence in The Urinary BladderSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.